Loading...
•
Mar 31, 2022
Matinas BioPharma Q1 2022 Earnings Report
Matinas BioPharma reported financial results for Q1 2022 and provided a corporate update.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $6.0 million, or $0.03 per share, for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $43.9 million as of March 31, 2022, which is expected to fund operations through 2023.
Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas’ proprietary LNC platform technology.
50% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data Expected Q3 2022.
Feedback from Clinical Type C Meeting with the FDA Provides Potential Pathway to NDA Submission for MAT2203 with a Single Confirmatory Trial for Both Induction and Consolidation Indications.
Successful Second In Vivo Efficacy Study of Oral LNC-Remdesivir.